Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral ...

Wolfe Research started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report published on Friday, MarketBeat reports. The brokerage issued a peer perform rating on the medical research ...

Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot, MariTide, causes excessive bone mineral density loss. Please watch the video at Investors.com - How ...

Amgen is expanding its attempts to enter the market for cardiometabolic drugs. That means it could soon compete in one of the most lucrative markets out there. But the established winners in that ...

Analysts' ratings for Amgen (NASDAQ:AMGN) over the last quarter vary from bullish to bearish, as provided by 11 analysts. The following table encapsulates their recent ratings, offering a glimpse ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value. The data, spotted by an analyst at Cantor Fitzgerald, focused on ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in the fast ...

THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The ...

THOUSAND OAKS, Calif., Oct. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, 2024, after the ...

Amgen’s Phase 1 data shows no association between MariTide and bone mineral density changes, supporting its safety claims. Analyst highlights that study data suggests a 4% BMD decrease at the ...

Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new cardiometabolic medicines for big-ticket indications like obesity and type 2 diabetes, ...